

22 April 2026

ASX Announcement

Appointment of Dr Marthe D'Ombra as Chief Scientific Officer

PolyNovo Limited ("**PolyNovo**" or the "**Company**"), a leading medical technology company transforming the management of complex wounds, is pleased to announce the appointment of Dr. Marthe D'Ombra as Chief Scientific Officer (**CSO**), effective 1 June 2026.

Dr D'Ombra is a highly accomplished biotech, science and innovation leader with 20+ years' experience spanning R&D strategy, portfolio development, external innovation, global licensing and commercialisation, with deep expertise across discovery science to translation.

Most recently, Dr D'Ombra served as the Executive Director & Head, Global Research Innovation at CSL, where she contributed to enterprise-level scientific direction and long-term R&D portfolio strategy. In her leadership roles, Dr D'Ombra founded and scaled CSL's global Research External Innovation division and established a global external innovation strategy aligned to enterprise therapeutic priorities to build and diversify CSL's R&D portfolio, delivering multiple programs into CSL's Research portfolio.

Dr D'Ombra is currently a non-executive director of AusBiotech and is a former non-executive director of Jumar BioIncubator. She has an extensive global network of academic organisations, biotech companies and venture capital partners and is experienced in negotiating complex global licensing agreements and milestone-based research collaborations across public and private sectors.

Beyond her scientific expertise, Dr D'Ombra brings deep governance and stakeholder engagement capability, including experience operating within publicly listed company governance frameworks and investor-facing environments.

Dr D'Ombra holds a PhD (Immunology and Microbiology) from the Walter & Eliza Hall Institute of Medical Research (WEHI) and The University of Melbourne and has 13 peer-reviewed publications. Prior to joining CSL, Dr D'Ombra held senior roles in Development and Partnerships at WEHI. She is also a Graduate of the Australian Institute of Company Directors.


CEO comment:

PolyNovo Chief Executive Officer Bruce Peatey said:

"Marthe's appointment reinforces our focus on building a leadership team capable of driving sustainable innovation and long-term growth at PolyNovo. She brings strategic R&D leadership, strong external partnership capability and a track record of translating scientific innovation into pipeline growth outcomes. Marthe's experience within a global, listed biotechnology organisation will play a key role in advancing and scaling the NovoSorb® platform as PolyNovo enters its next phase of development."



PolyNovo Limited (ASX: PNV) ABN 96 083 866 862
2/320 Lorimer Street, Port Melbourne, Victoria 3207 Australia
+61 3 8681 4050 investor@polynovo.com
investors.polynovo.com



Dr. Marthe D'Ombra comment:

"PolyNovo has established a track record of science-led innovation aimed at improving outcomes in complex wounds. I am excited to join the Company and look forward to drawing on my global experience in scientific innovation, research translation and external partnerships alongside PolyNovo's global team to accelerate the velocity of the pipeline and support continued global growth."

This announcement has been authorised for release by PNV's Company Secretary, Amy Demediuk.

Further information:

Amy Demediuk, General Counsel & Company Secretary

Mobile: + 61 419 858 691

Email: amy.d@polynovo.com

Media contact:

media@polynovo.com

About PolyNovo®

PolyNovo (ASX: PNV) is a leading medical technology company transforming the management of complex wounds. Headquartered in Melbourne, Australia, it has international operations in the United States, United Kingdom, India, Hong Kong and Singapore and several other markets supported by distributor partners.

The proprietary NovoSorb® polymer is addressing significant unmet needs in wound care, as evidenced by its clinical adoption and patient outcomes, and the Company is leveraging the technology platform to develop new products and markets.

Achievements to date, including continued revenue growth, profitability, numerous clearances and registrations, as well as market leadership in several geographies, provide a strong foundation for continued growth.

For more information see polynovo.com

About NovoSorb® Technology

NovoSorb® is a proprietary biodegradable polymer platform designed to support tissue regeneration in complex wound care. The unique characteristics of NovoSorb® provide several key advantages including excellent biocompatibility, control over physical properties, a programmable bio-resorption profile and can be produced in many formats including film, fibre, foam, and coatings.

NovoSorb® BTM is a synthetic dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma or burn. This innovative product was the first to be commercially available utilising NovoSorb® technology and is supported by a growing body of independent clinical evidence.

NovoSorb® MTX is PolyNovo's latest advanced wound care product; a fully synthetic dermal matrix, developed in response to surgeon demand for a dermal substitute without a temporising, sealing membrane. Since receiving FDA 510(k) clearance in 2022, NovoSorb® MTX has rapidly gained surgeon adoption and is emerging as a key driver of growth.

[View this announcement on PolyNovo's investor hub](#)